Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

<div class="b2iNewsItemSubheadDiv">Allowed claims cover the detection of select genotypes for use of AD04 to treating AUD and OUD patients</div><div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="justify">CHARLOTTESVILLE, Va., Oct. 19, 2023 (GLOBE NEWSWIRE) -- <strong>Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) </strong>("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on...